{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-099969","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2025-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.233344+00:00","generated_at":"2026-05-17T03:24:41.688215+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Hoth Therapeutics updates corporate presentation with clinical milestones and cash position","bullets":["HT-001 Phase 2a open-label cohort showed promising results; case study published Sept 2024.","HT-KIT IND-enabling tox studies initiated Q1 2024; target IND submission Q4 2026.","HT-ALZ patent awarded Q3 2024; preclinical studies at Washington University completed.","HT-VA license from Veteran's Affairs obtained Q1 2025; CRADA executed Q2 2025.","15.4M shares outstanding as of Oct 14, 2025; cash sufficient for clinical and preclinical programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-099969","json":"https://secwatch.observer/filing/0001213900-25-099969.json","markdown":"https://secwatch.observer/filing/0001213900-25-099969.md","text":"https://secwatch.observer/filing/0001213900-25-099969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025099969/0001213900-25-099969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390025099969/ea0261354-8k_hoth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:24:41.688215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}